Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 4.2.2012 | EN | Official Journal of the European Union | C 32/13 |

---

Reference for a preliminary ruling from the Landgericht Düsseldorf (Germany), lodged on 16 November 2011 — Novartis AG v Actavis Deutschland GmbH & Co KG, Actavis Ltd.

(Case C-574/11)

2012/C 32/24

Language of the case: German

Referring court

Landgericht Düsseldorf

Parties to the main proceedings

Applicant: Novartis AG

Defendants: Actavis Deutschland GmbH & Co KG, Actavis Ltd.

Question referred

Are Articles 4 and 5 of Regulation (EC) No 469/2009[(1)](#ntr1-C_2012032EN.01001303-E0001) to be interpreted as meaning that the protection conferred by a supplementary protection certificate, which has been granted for a single active ingredient (in this case, Valsartan), extends to a form which contains a combination of active ingredients featuring that single active ingredient (in this case, Valsartan + Hydrochlorothiazide)?

---

[Top](#document1)